PL4082334T3 - Zwierzęta inne niż człowiek posiadające zmodyfikowane locus łańcucha lekkiego lambda immunoglobuliny - Google Patents

Zwierzęta inne niż człowiek posiadające zmodyfikowane locus łańcucha lekkiego lambda immunoglobuliny

Info

Publication number
PL4082334T3
PL4082334T3 PL22164751.4T PL22164751T PL4082334T3 PL 4082334 T3 PL4082334 T3 PL 4082334T3 PL 22164751 T PL22164751 T PL 22164751T PL 4082334 T3 PL4082334 T3 PL 4082334T3
Authority
PL
Poland
Prior art keywords
light chain
human animals
chain locus
lambda light
engineered immunoglobulin
Prior art date
Application number
PL22164751.4T
Other languages
English (en)
Inventor
Chunguang GUO
Faith HARRIS
Vera VORONINA
John Mcwhirter
Natasha Levenkova
Lynn Macdonald
Naxin Tu
Andrew J Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of PL4082334T3 publication Critical patent/PL4082334T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL22164751.4T 2016-11-04 2017-11-03 Zwierzęta inne niż człowiek posiadające zmodyfikowane locus łańcucha lekkiego lambda immunoglobuliny PL4082334T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662417845P 2016-11-04 2016-11-04
US201762567932P 2017-10-04 2017-10-04

Publications (1)

Publication Number Publication Date
PL4082334T3 true PL4082334T3 (pl) 2025-08-11

Family

ID=62025924

Family Applications (3)

Application Number Title Priority Date Filing Date
PL22164751.4T PL4082334T3 (pl) 2016-11-04 2017-11-03 Zwierzęta inne niż człowiek posiadające zmodyfikowane locus łańcucha lekkiego lambda immunoglobuliny
PL17863293T PL3407709T3 (pl) 2016-11-04 2017-11-03 Zwierzęta inne niż człowiek posiadające zmodyfikowany sposobami inżynierii locus łańcucha lekkiego lambda immunoglobuliny
PL20180508.2T PL3766343T3 (pl) 2016-11-04 2017-11-03 Zwierzęta inne niż człowiek posiadające zmodyfikowany sposobami inżynierii locus łańcucha lekkiego lambda immunoglobuliny

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL17863293T PL3407709T3 (pl) 2016-11-04 2017-11-03 Zwierzęta inne niż człowiek posiadające zmodyfikowany sposobami inżynierii locus łańcucha lekkiego lambda immunoglobuliny
PL20180508.2T PL3766343T3 (pl) 2016-11-04 2017-11-03 Zwierzęta inne niż człowiek posiadające zmodyfikowany sposobami inżynierii locus łańcucha lekkiego lambda immunoglobuliny

Country Status (26)

Country Link
US (2) US10820582B2 (pl)
EP (4) EP4082334B1 (pl)
JP (5) JP6884860B2 (pl)
KR (4) KR102492433B1 (pl)
CN (2) CN109996441B (pl)
AU (2) AU2017391167B2 (pl)
BR (1) BR112019008675A2 (pl)
CA (1) CA3038720A1 (pl)
CY (2) CY1123491T1 (pl)
DK (3) DK3766343T3 (pl)
ES (3) ES2915609T3 (pl)
FI (1) FI4082334T3 (pl)
HR (3) HRP20220888T1 (pl)
HU (3) HUE052087T2 (pl)
IL (2) IL266282B2 (pl)
LT (3) LT4082334T (pl)
MA (2) MA44091A (pl)
MX (2) MX385857B (pl)
PL (3) PL4082334T3 (pl)
PT (3) PT4082334T (pl)
RS (3) RS66884B1 (pl)
RU (2) RU2021129958A (pl)
SG (2) SG10201913483XA (pl)
SI (3) SI3766343T1 (pl)
SM (3) SMT202000558T1 (pl)
WO (1) WO2018128691A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
EP2597945B1 (en) 2010-07-26 2020-07-22 Trianni, Inc. Transgenic animals and methods of use
WO2013116609A1 (en) * 2012-02-01 2013-08-08 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
CA3038720A1 (en) 2016-11-04 2018-07-12 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
US20210051929A1 (en) 2018-03-24 2021-02-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CA3093850A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
IL318469A (en) * 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
US11464217B2 (en) 2019-02-22 2022-10-11 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
EP3993623B1 (en) * 2019-07-01 2025-02-19 Trianni, Inc. Transgenic rodents and methods of use thereof
IL298632A (en) * 2020-06-02 2023-01-01 Biocytogen Pharmaceuticals Beijing Co Ltd Non-human animals genetically modified with a common light chain immunoglobulin locus
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
IL303868A (en) 2020-12-23 2023-08-01 Regeneron Pharma Nucleic acids encoding anchor-modified antibodies and uses thereof
GB202217978D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0746609A4 (en) * 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1461442B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
KR101711222B1 (ko) * 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
ES2948572T3 (es) * 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
MY195217A (en) 2010-06-22 2023-01-11 Regeneron Pharma MICE Expressing An Immunoglobulin Hybrid Light Chain
HUE024534T2 (hu) 2011-02-25 2016-01-28 Regeneron Pharma ADAM6 egerek
US10246509B2 (en) 2011-10-17 2019-04-02 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG11201403326VA (en) 2011-12-20 2014-07-30 Regeneron Pharma Humanized light chain mice
CN109913495B (zh) 2013-02-20 2022-11-25 瑞泽恩制药公司 大鼠的遗传修饰
SMT201800435T1 (it) * 2013-02-20 2018-09-13 Regeneron Pharma Animali non umani con sequenze della catena pesante dell’immunoglobulina modificate riferimento incrociato a domande correlate
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
ES2993142T3 (en) * 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
JP6174811B2 (ja) 2013-12-11 2017-08-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ゲノムの標的改変のための方法及び組成物
MX385689B (es) 2014-06-06 2025-03-18 Regeneron Pharma Métodos y composiciones para modificar un locus dirigido.
US9738897B2 (en) 2014-06-23 2017-08-22 Regeneron Pharmaceuticals, Inc. Nuclease-mediated DNA assembly
ES2731437T3 (es) 2014-11-21 2019-11-15 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
MX388784B (es) 2014-12-19 2025-03-20 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida a través de direccionamiento múltiple de una sola etapa.
CA3038720A1 (en) 2016-11-04 2018-07-12 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus

Also Published As

Publication number Publication date
SI4082334T1 (sl) 2025-06-30
BR112019008675A2 (pt) 2019-07-09
SI3766343T1 (sl) 2022-06-30
CN109996441B (zh) 2022-02-08
US20180125043A1 (en) 2018-05-10
PL3407709T3 (pl) 2021-01-11
US20210029978A1 (en) 2021-02-04
RS66884B1 (sr) 2025-07-31
DK3766343T3 (da) 2022-06-20
US10820582B2 (en) 2020-11-03
KR20240055863A (ko) 2024-04-29
MX385857B (es) 2025-03-18
DK4082334T3 (da) 2025-06-02
HUE061980T2 (hu) 2023-09-28
EP4567119A2 (en) 2025-06-11
JP2025166207A (ja) 2025-11-05
LT3407709T (lt) 2020-10-12
FI4082334T3 (fi) 2025-06-10
MA53935A (fr) 2021-12-22
US12433264B2 (en) 2025-10-07
PL3766343T3 (pl) 2022-09-26
SI3407709T1 (sl) 2020-10-30
JP2023053400A (ja) 2023-04-12
IL266282A (en) 2019-06-30
EP4082334B1 (en) 2025-03-26
HRP20201403T1 (hr) 2020-11-27
NZ753456A (en) 2021-08-27
EP4567119A3 (en) 2025-09-24
MX2021010556A (es) 2021-10-01
MX2019005256A (es) 2019-08-05
JP7386292B2 (ja) 2023-11-24
CY1123491T1 (el) 2022-03-24
AU2017391167A1 (en) 2019-05-30
MA44091A (fr) 2018-10-24
PT3407709T (pt) 2020-08-20
JP2021090455A (ja) 2021-06-17
SG10201913483XA (en) 2020-03-30
SMT202200259T1 (it) 2022-07-21
ES3035365T3 (en) 2025-09-02
RS60886B1 (sr) 2020-11-30
SMT202500204T1 (it) 2025-07-22
HUE052087T2 (hu) 2021-04-28
HUE071595T2 (hu) 2025-09-28
KR102319069B1 (ko) 2021-11-01
IL266282B2 (en) 2024-04-01
RU2757665C2 (ru) 2021-10-20
PT3766343T (pt) 2022-05-30
EP3766343B1 (en) 2022-05-11
LT3766343T (lt) 2022-06-10
RU2019112589A3 (pl) 2021-03-30
KR102492433B1 (ko) 2023-01-30
PT4082334T (pt) 2025-05-21
IL308197A (en) 2024-01-01
JP6884860B2 (ja) 2021-06-09
CN114369157A (zh) 2022-04-19
ES2823305T3 (es) 2021-05-06
EP4082334A1 (en) 2022-11-02
KR20230020550A (ko) 2023-02-10
IL266282B1 (en) 2023-12-01
ES2915609T3 (es) 2022-06-23
EP3407709B1 (en) 2020-07-29
KR102658529B1 (ko) 2024-04-19
KR20210134059A (ko) 2021-11-08
LT4082334T (lt) 2025-05-26
AU2017391167B2 (en) 2024-02-15
CY1125474T1 (el) 2025-05-09
JP2020501516A (ja) 2020-01-23
JP2022130725A (ja) 2022-09-06
SMT202000558T1 (it) 2020-11-10
RU2021129958A (ru) 2021-11-02
DK3407709T3 (da) 2020-08-31
RS63390B1 (sr) 2022-08-31
WO2018128691A8 (en) 2019-02-28
RU2019112589A (ru) 2020-12-04
HRP20250695T1 (hr) 2025-08-01
CA3038720A1 (en) 2018-07-12
KR20190076024A (ko) 2019-07-01
SG11201903344XA (en) 2019-05-30
EP3407709B9 (en) 2021-10-06
EP3407709A1 (en) 2018-12-05
WO2018128691A1 (en) 2018-07-12
AU2024200582A1 (en) 2024-03-28
CN109996441A (zh) 2019-07-09
EP3766343A1 (en) 2021-01-20
HRP20220888T1 (hr) 2022-10-28

Similar Documents

Publication Publication Date Title
IL266282A (en) Non-human animals with a transgenic immunoglobulin light chain locus
IL274797A (en) Non-human animals with engineered immunoglobulin light chain and uses thereof
LT3597037T (lt) Humanizuoti gyvūnai, išskyrus žmones, su apribotu imunoglobulino sunkiosios grandinės lokusu
HUE054612T2 (hu) Humanizált limfocitaaktiváló gén 3-t tartalmazó nem-humán állatok
DK3129400T3 (da) Ikke-humane dyr med humaniserede Fc-gamma-receptorer
IL253579A0 (en) Anti-light chain substituent antibodies
IL268049A (en) Human antibodies from transgenic rodents with multiple immunoglobulin heavy chain LOCIs
SG11201802698XA (en) Transgenic rabbit with common light chain